SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Partin AW, Brawer MK, Bartsch G et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003; 170: 178791
  • 2
    Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol 2001; 165: 19306
  • 3
    Horninger W, Cheli CD, Babaian RJ et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2–4 nanograms per milliliter. Urology 2002; 60 (Suppl. 1): 315
  • 4
    Miller MC, O’Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 2001; 57: 110511
  • 5
    Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001; 165: 154953
  • 6
    Brawer MK. Clinical usefulness of assays for complexed prostate-specific antigen. Urol Clin North Am 2002; 29: 193203, xi
  • 7
    Djavan B, Remzi M, Zlotta AR et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002; 60 (Suppl. 1): 49
  • 8
    Veltri RW, Miller MC, O’Dowd GJ, Partin AW. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 2002; 60 (Suppl. 1): 4752
  • 9
    Jung K, Lein M, Butz H, Stephan C, Loening SA, Keller T. New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics. J Urol 2006; 175: 127580
  • 10
    Babaian RJ, Naya Y, Cheli C, Fritsche HA. The detection and potential economic value of complexed prostate specific antigen as a first line test. J Urol 2006; 175: 897901
  • 11
    Martin BJ, Cheli CD, Sterling K et al. Prostate specific antigen isoforms and human glandular kallikrein 2 – which offers the best screening performance in a predominantly black population? J Urol 2006; 175: 1047
  • 12
    Roddam AW, Duffy MJ, Hamdy FC et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/mL: systematic review and meta-analysis. Eur Urol 2005; 48: 38699
  • 13
    Sozen S, Eskicorapci S, Kupeli B et al. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/mL: results of a prospective multicenter study. Eur Urol 2005; 47: 3027
  • 14
    Okihara K, Ukimura O, Nakamura T et al. Complexed PSA improves prostate cancer detection: results from a multicenter Japanese clinical trial. Urology 2006; 67: 32832
  • 15
    Herrmann W, Stockle M, Sand-Hill M et al. The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen. Clin Chem Lab Med 2004; 42: 10517
  • 16
    Parsons JK, Partin AW. Applying complexed prostate-specific antigen to clinical practice. Urology 2004; 63: 8158
  • 17
    Moul JW. Variables in predicting survival based on treating ‘PSA-only’ relapse. Urol Oncol 2003; 21: 292304
  • 18
    Allard WJ, Cheli CD, Morris DL et al. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay. Int J Biol Markers 1999; 14: 7383
  • 19
    Sokoll LJ, Mangold LA, Partin AW et al. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. Urology 2002; 60 (Suppl. 1): 1823
  • 20
    Gordis L. Assessing the validity and reliability of diagnostic and screening tests. Epidemiology, 2nd Edn. Philadelphia: Elsevier Saunders, 2004: 5876